What are the introduction, staging, diagnostic workup, and management options for gastrointestinal stromal tumor (GIST)?

Gastrointestinal Stromal Tumor (GIST): Comprehensive Management

Introduction

GIST is the most common malignant mesenchymal neoplasm of the gastrointestinal tract, driven predominantly by gain-of-function mutations in KIT (75-80%) or PDGFRA (10-15%) receptor tyrosine kinases, making it a paradigmatic model for targeted therapy in oncology. 1 The disease spans a clinical spectrum from essentially benign tumors to aggressive metastatic disease. 2 GISTs occur throughout the GI tract, with the stomach being the most frequent site (60-70%), followed by small intestine (25-30%), rectum, esophagus, and colon (each <5%). 3

Diagnostic Workup

Initial Assessment by Tumor Size and Location

For gastric nodules <2 cm: Perform endoscopic ultrasound (EUS) assessment with biopsy if feasible. 1 If GIST is confirmed, resection should be performed unless major morbidity is expected (e.g., esophagogastric junction, medial aspect of second duodenal portion). 1 Active surveillance is an acceptable alternative depending on patient age, life expectancy, and comorbidities, with short-term reassessment at 3 months, then extended intervals if no growth. 1

For gastric tumors ≥2 cm: Biopsy or excision is standard due to higher progression risk. 1

For rectal nodules (any size): Biopsy or excision after endorectal ultrasound and pelvic MRI is mandatory regardless of size, as rectal GISTs carry higher progression risk and worse prognosis than gastric primaries. 1 Examination under anesthesia may be considered. 1

For large masses requiring multivisceral resection: Multiple core needle biopsies via EUS guidance or CT/ultrasound-guided percutaneous approach are standard to enable mutational analysis and consideration of neoadjuvant therapy. 1 The risk of peritoneal contamination or bleeding is negligible when properly performed. 1

Imaging

• CT scan is the primary imaging modality for identification and staging. 4
• Pelvic MRI is essential for rectal GISTs to assess anatomic relationships to the sphincter complex. 1
• EUS is critical for small gastric lesions to guide biopsy decisions. 1

Pathological Diagnosis

Diagnosis relies on morphology and immunohistochemistry, typically positive for CD117 (KIT) and/or DOG1. 1 Approximately 5% of GISTs are CD117-negative. 1 Tumor samples should be fixed in 4% buffered formalin (not Bouin fixative, which prevents molecular analysis). 1

Mutational analysis for KIT and PDGFRA is mandatory before initiating systemic therapy, as it confirms diagnosis in doubtful cases and guides treatment selection. 1, 5 This is particularly critical for CD117/DOG1-negative GISTs and for planning neoadjuvant or adjuvant therapy. 1

Prognostic Assessment

Mitotic count expressed as number of mitoses per 5 mm² area (replacing the 50 high-power field method) is essential for risk stratification. 1 This is a continuous variable and should be reported as such. 1 Ki-67 does not replace mitotic count and is not part of established prognostic systems. 1

Staging and Risk Stratification

Risk stratification is based on:

• Tumor size (continuous variable)
• Mitotic rate (per 5 mm²)
• Anatomic location (gastric vs. non-gastric)
• Tumor rupture (spontaneous or surgical)

1, 4

Note: Current risk stratification models are inaccurate for SDH-deficient GIST, and uncertainty remains regarding adjuvant therapy for this subtype. 1

Management

Localized Disease

Surgical Principles

All GIST management should occur within experienced multidisciplinary teams at specialist centers. 1, 6

For small, low-risk tumors: Surgical excision is standard. 7 Endoscopic resection is acceptable when complete excision without tumor rupture is technically feasible, minimizing morbidity. 1

For rectal GISTs: Surgical strategy must be tailored to precise anatomic site and sphincter relationship. 1 Approaches include pararectal incisions, transanal approaches (including TAMIS), minimally invasive/robotic surgery, or abdominoperineal resection. 1 Organ-preserving approaches should be prioritized when possible. 1

Neoadjuvant Therapy

Pre-operative imatinib should be considered for primaries where immediate resection would be highly morbid (e.g., total gastrectomy, abdominoperineal resection, multivisceral resection). 1 This is particularly valuable for large rectal tumors, facilitating more marginal excision when tumors demonstrate imatinib response. 1

Mutational analysis is mandatory prior to initiating neoadjuvant imatinib to ensure the tumor is not resistant (particularly excluding PDGFRA exon 18 D842V mutations). 1

Adjuvant Therapy

Patients at high risk of recurrence should receive 3 years of adjuvant imatinib at 400 mg daily, provided their tumor is not likely resistant (particularly excluding PDGFRA D842V mutations). 1

For tumor rupture (spontaneous or surgical): These patients face very high risk of peritoneal relapse due to tumor cell spillage. 1 They should receive adjuvant imatinib for at least 3 years, and probably lifelong, as they essentially have occult metastatic disease. 1

Advanced/Metastatic Disease

First-Line Therapy

Imatinib 400 mg daily is the standard first-line treatment for inoperable and metastatic GIST. 1, 7 This includes patients who previously received adjuvant imatinib without relapse during treatment. 1

For KIT exon 9 mutations: The standard dose is 800 mg daily, which provides superior progression-free survival and overall survival (hazard ratio 0.54) compared to 400 mg daily. 1

Treatment must be continued indefinitely, as interruption typically leads to rapid tumor progression, even when lesions have been surgically excised. 1

Subsequent Lines

Sunitinib is required for progression on imatinib, particularly for KIT exon 9,13, and 14 mutations. 4, 7

Regorafenib is standard third-line therapy for highly refractory tumors. 1, 4, 7

Ripretinib and avapritinib hold regulatory approval for later-line treatment. 2

Ponatinib is used for KIT exon 17 mutations. 4

Surgery in Metastatic Setting

Surgery can be clinically relevant in metastatic disease for selected patients, though it is not recommended as a primary approach to metastatic GIST. 1, 7 The liver is the most common metastatic site. 3

Special Considerations

For unresectable rectal GISTs: Radiotherapy may be considered after or in addition to systemic therapy to maintain local control when surgery is not feasible. 1

For PDGFRA D842V mutations: Tyrosine kinase inhibitors have no or limited efficacy; avapritinib is the specific agent for this mutation. 7, 2

For KIT/PDGFRA wild-type GISTs: Standard TKIs have limited efficacy. 7

Follow-Up

High-risk tumors should be monitored with serial abdominal CT scans to detect recurrence. 4 Rectal GISTs have a relatively high recurrence rate post-surgery and marked regional sensitivity to imatinib, indicating benefit for management in specialist centers. 1

Common Pitfalls

• Failing to obtain mutational analysis before starting systemic therapy prevents optimal treatment selection and may lead to ineffective therapy (e.g., imatinib for PDGFRA D842V). 1
• Using Bouin fixative prevents molecular analysis; always use 4% buffered formalin. 1
• Interrupting TKI therapy in responding patients leads to rapid progression. 1
• Performing surgery as primary approach in metastatic disease without considering neoadjuvant therapy misses opportunities for less morbid resections. 1
• Inadequate duration of adjuvant therapy (less than 3 years in high-risk patients) increases recurrence risk. 1